All News

The COVID-19 pandemic brought on a huge surge in the use of telemedicine for cancer care, but now as the pandemic is slowing down, an expert said that there are certain times when telemedicine will do, while other situations warrant an in-person visit with the doctor.

Going through the COVID-19 pandemic with a cancer diagnosis made me feel jittery, and I know that many others felt the same way, too.

An upcoming phase 2 study will explore if the transdermal (through the skin) delivery of a drug commonly used to treat nausea and vomiting will result in no nausea, no vomiting and no use of rescue medicines in patients with cancer receiving chemotherapy.

Watch Dr. Saad Z. Usmani, Dr. Ben Marcus and Stan Wagner discuss their participation in the Moving Mountains for Multiple Myeloma program, during the CURE Educated Patient Multiple Myeloma Summit.

The plan is to assess the safety and efficacy of the genetically engineered cell therapy alongside high-dose chemotherapy and blood stem cell transplantation in approximately 150 patients with lymphoma.

Monumental treatment advancements over the past two decades have given patients with thyroid cancer the ability to live longer and better lives, according to an expert from Cleveland Clinic’s Taussig Cancer Institute. However, more work is needed to find curative treatments.

After being diagnosed with cancer, I scoured the internet for ways to live as long as possible and found some helpful tips and not-so-helpful “cures.”

“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.

Watch Kristie L. Kahl, Donna and Jack McNutt, Dr. Noopur Raje, and Grace Allison, discuss treating myeloma long term, during the CURE Educated Patient Multiple Myeloma Summit.

A patient with an advanced solid tumor was given their first dose of a novel antibody, kicking off a phase 1/1b study comparing this drug with or without Keytruda in patients with several types of solid tumors.

Certain patients with metastatic breast cancer may benefit from Enhertu compared with standard of care with Kadcyla despite higher rates of side effects including lung inflammation and interstitial lung disease.

When visiting the cancer center (or any other health care center), the people who greet me at the front desk can have a major impact on the whole experience.

The FDA’s decision to approve Yescarta in patients with large B-cell lymphoma that has failed to respond to first-line treatment is based on data that showed that the use of the CAR-T cell therapy resulted in a significant increase in patients who were alive at two years compared with the standard-of-care second-line treatment.

Watch Dr. Saad Z. Usmani, Dr. Krina K. Patel, Dr. Noa Biran, and Jenny Ahlstrom, answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

Watch Dr. Noa Biran, an associate professor of medicine in the division of multiple myeloma at The John Theurer Cancer Center at Hackensack University Medical Center, discuss treatment for relapsed/refractory myeloma.

The year 2022 has already been filled with obstacles and heartache — as well plans for a new cancer treatment — but I’m putting away the bad thoughts to get ready for the fight ahead of me.

Watch Dr. Krina K. Patel, an associate professor and center medical director for the Department of Lymphoma-Myeloma at The University of Texas MD Anderson Cancer Center discuss treatment for newly diagnosed myeloma.

In CURE’s Speaking Out video series, on behalf of Living Beyond Breast Cancer, Andrea Kassem discusses integrative care in metastatic breast cancer.

In CURE’s Speaking Out video series, on behalf of Living Beyond Breast Cancer, Dr. Nancy Lin discusses treatment planning for patients with breast cancer that has metastasized to the brain.

In CURE’s Speaking Out video series, on behalf of Living Beyond Breast Cancer, Myra Camino discusses her experience as a patient advocating for herself after her stage 4 metastatic breast cancer diagnosis.

In CURE’s Speaking Out video series, on behalf of Living Beyond Breast Cancer, Dr. Nancy Lin discusses the multidisciplinary approach to metastatic breast cancer care.

Treatment with a novel monotherapy in a patient with relapsed/refractory acute myeloid leukemia was effective enough that a successful, as indicated by a significant reduction in bone marrow blasts, stem cell transplant was performed.

Motivating affirmations are one thing, but to me, labels like “survivor” and “cancer-free” are a touchy subject.

From New York Yankees outfielder Aaron Judge giving a brain cancer survivor custom baseball cards to Tom Parker’s brain cancer death and Good Morning America’s Robin Roberts opening up about her cancer experience, here’s what is happening in the cancer space this week.

Watch Saad Z. Usmani, MD, MBA, with Carlyn Rose Tan, MD; Neha S. Korde, MD; and Kenny Capps answer audience Q&A during the CURE Educated Patient Multiple Myeloma Summit.

The FDA plans to decide on whether to approve futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors a certain genetic mutation by September.

Patients with colorectal cancer that has spread to the liver tend to have poor outcomes and are typically not candidates to receive liver transplants from deceased donors. However, results from a small study on transplanting livers from live-donors could "change this paradigm," an expert said.

Twice a week, my local Gilda’s Club holds a “Lunch and Laughs” group meeting with cancer survivors that has kept me grounded through COVID-19 isolation and beyond.

As a patient moves from treatment to survivorship, the fear of cancer recurrence may overshadow the ability for them to recognize how much they have endured, but support is available to hopefully lessen the burden.

Watch Dr. Carlyn Rose Tan, an assistant attending in myeloma service at Memorial Sloan Kettering Cancer Center, present on risk stratification for newly diagnosed patients.